Literature DB >> 10463077

Antisense technologies have a future fighting neurodegenerative diseases.

S Seidman1, F Eckstein, M Grifman, H Soreq.   

Abstract

Our growing understanding of the role that unfavorable patterns of gene expression play in the etiology of neurodegenerative disease emphasizes the need for strategies to selectively block the biosynthesis of harmful proteins in the brain. Antisense technologies are ideally suited to this purpose. Tailor-designed to target specific RNA, antisense oligonucleotides and ribozymes offer tools to suppress the production of proteins mediating neurodegeneration. Although technical limitations must still be overcome, the antisense approach represents a novel and exciting strategy for intervention in diseases of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463077     DOI: 10.1089/oli.1.1999.9.333

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  5 in total

1.  Synaptogenesis and myopathy under acetylcholinesterase overexpression.

Authors:  E Lev-Lehman; T Evron; R S Broide; E Meshorer; I Ariel; S Seidman; H Soreq
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

2.  Improved hybridisation potential of oligonucleotides comprising O-methylated anhydrohexitol nucleoside congeners.

Authors:  A Van Aerschot; M Meldgaard; G Schepers; F Volders; J Rozenski; R Busson; P Herdewijn
Journal:  Nucleic Acids Res       Date:  2001-10-15       Impact factor: 16.971

Review 3.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

4.  Nanogels for oligonucleotide delivery to the brain.

Authors:  Serguei V Vinogradov; Elena V Batrakova; Alexander V Kabanov
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

Review 5.  RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

Authors:  Stéphane Mathis; Gwendal Le Masson
Journal:  Biomedicines       Date:  2018-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.